The British pharmaceutical company, GlaxoSmithKline, has issued a recall of nearly 600,000 albuterol inhalers, sold under the trade name Ventolin HFA. The recall is intended for retailers, wholesalers, hospitals and pharmacies who may have the questionable lots on their shelves for distribution.
The issue with the recalled inhalers is a suspected leak in the device that has been noted because the plastic overwrap has been inflated upon first opening the package. Such leakage may result in each inhaler delivering fewer doses than what the dosage meter indicates.
Again, this is not a consumer-level recall, since the affected inhalers should still be at their distribution sites, but if you or someone you know with a Ventolin HFA 200D inhaler has any questions, calls should be directed to GSK’s customer response site at 1-888-825-5249.
Even though it is unlikely that consumers have one of the recalled inhalers, if the inhalers you have fails to relieve symptoms, the company advises you to seek emergency medical treatment.
Lot numbers for the voluntarily recalled inhalers, manufactured by GSK plant in Zebulon, North Carolina are:
Ventolin (albuterol) is used in the treatment of asthma and chronic obstructive pulmonary disease, or COPD as a quick relief medication when breathing difficulties occur.
GSK released this statement in regard to it voluntary recall of the Ventolin HFA 200D inhalers:
Share with your friendsFollow Us
“Though the overall benefit-risk assessment for Ventolin® HFA 200D Inhaler when used at prescribed doses remains favourable, in this situation, there is possible risk to patients of experiencing diminished bronchodilation in the setting of acute bronchospasm if reliant on a rescue inhaler that could potentially not deliver the stated number of actuations. GSK is committed to supplying high quality product and patient satisfaction, and we sincerely regret any inconvenience this recall may cause.”